What Are Biologics for Severe Asthma and Who Qualifies?

Biologic therapies (often called “biologics”) are advanced medications used as add-on treatments for people with severe asthma that remains uncontrolled despite the regular use of high-dose daily inhalers ^[1]. Administered as injections or infusions, biologics are not rescue inhalers or steroids. Rather, they are monoclonal antibodies (specialized, lab-made proteins) designed to target and block specific parts of the immune system that drive airway inflammation ^[2]. For some patients, biologics can substantially reduce severe asthma flare-ups (exacerbations) and decrease the need for oral steroid pills ^[3]. Biologics do not treat sudden breathing difficulties or acute asthma attacks; always follow your asthma action plan and seek emergency care when indicated.

How Do Biologics Target the Immune System?

Asthma is not a single disease. It is driven by different underlying inflammatory pathways (often referred to as asthma phenotypes) ^[3]. Biologics are highly specific and target particular chemical messengers or cells involved in your specific pattern of inflammation. The main targets include:

• Anti-IgE (Omalizumab): Targets Immunoglobulin E (IgE), an antibody that triggers allergic reactions. This medication is typically considered for severe allergic asthma ^[2]. Selecting this biologic involves assessing not only IgE levels but also body weight and documented allergies to year-round allergens ^[4].
• Anti-IL-5 and IL-5 Receptor (Mepolizumab, Reslizumab, Benralizumab, Depemokimab): Target Interleukin-5 (IL-5) or its receptor (the docking station on a cell). IL-5 is a chemical messenger that promotes the growth of eosinophils (a type of white blood cell that contributes to swelling and inflammation in the airways). Blocking IL-5 helps deplete these cells, making these drugs a primary option for severe eosinophilic asthma ^[5][6].
• Anti-IL-4 Receptor (Dupilumab): Binds to the Interleukin-4 receptor alpha, which blocks the signaling pathways for both Interleukin-4 (IL-4) and Interleukin-13 (IL-13) ^[7]. These pathways are key drivers of type 2 (allergic and eosinophilic) inflammation ^[8].
• Anti-TSLP (Tezepelumab): Targets a chemical messenger higher up in the inflammatory cascade (the chain of immune reactions), blocking multiple pathways simultaneously ^[9]. This option may be considered even if specific allergic or eosinophilic markers are not highly elevated ^[2].

Who Qualifies for Biologics?

Biologics are reserved for a specific group of patients. Availability, approved age limits, and insurance criteria vary significantly by country and healthcare system ^[10]. The evaluation usually involves several steps:

1. Uncontrolled Severe Asthma: You generally must have severe asthma that continues to cause frequent flare-ups or persistent symptoms despite optimized treatment with high-dose inhaled corticosteroids and at least one other daily controller medication ^[1].
2. Addressing Modifiable Factors: Doctors must first verify inhaler technique and adherence, while assessing other conditions that mimic or worsen asthma, such as acid reflux, obesity, chronic sinus issues, or environmental exposures ^[11]. Addressing these factors often improves symptoms enough that a biologic may no longer be needed ^[12].
3. Biomarker Evaluation: Your doctor will likely test biomarkers—such as a blood eosinophil count, IgE levels, and FeNO (a breath test measuring airway inflammation)—to help predict which biologic is most likely to help you ^[4]. However, these are not absolute pass/fail tests. Biomarker thresholds differ by drug and jurisdiction ^[13], and results can fluctuate or be influenced by recent steroid use ^[14].
4. Oral Steroid Use: Patients who rely on daily maintenance oral corticosteroids (like prednisone) may be considered for biologics, as a major goal of therapy is to safely reduce steroid exposure ^[15]. Meeting this criterion does not automatically qualify you for every drug, but it is an important consideration ^[16].

Important Safety Warning: If you take maintenance oral corticosteroids, never stop or taper them abruptly on your own ^[16]. Tapering must be gradual and supervised by a doctor. Abrupt withdrawal can cause dangerous adrenal insufficiency and trigger a severe asthma flare-up.

How Are They Administered and Are They Effective?

Most biologics for asthma are given as subcutaneous (under the skin) injections, though reslizumab is administered as an intravenous (IV) infusion ^[17]. Depending on the specific medication, country approvals, and your doctor’s assessment, injections are administered every 2, 4, or 8 weeks; newer options like depemokimab are being evaluated for dosing every 26 weeks in some regions ^[18]. While initial doses often require a clinic visit for monitoring, some biologics may be approved for patients to self-administer at home after proper training ^[19].

When matched to the right patient, biologics can substantially reduce severe asthma exacerbations and lower oral steroid use ^[20]. However, they are not a cure, and lung function or symptom improvements vary from person to person ^[21]. Your doctor will typically assess your response after several months of treatment to decide whether to continue or switch therapies ^[22].

Safety and Ongoing Care: While biologics reduce risk, they carry their own potential side effects. Common reactions include injection-site pain or swelling, headache, conjunctivitis (pink eye), and changes in eosinophil levels ^[23]. Severe allergic reactions (anaphylaxis) are a rare but serious risk that requires monitoring, and can occur beyond the first dose ^[24]. Do not stop your regular daily inhalers when starting a biologic; your doctor may adjust your controller medications later if your asthma remains well-controlled over time ^[1].